 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- GLPG5101 / Galapagos
Atalanta-1: A Phase 1/2 Trial of GLPG5101, a Fresh, Stem-like, Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma (Marriott Grand Ballroom 11-13 (Marriott Marquis San Diego Marina)) - Nov 6, 2024 - Abstract #ASH2024ASH_1640;
GLPG5101, a fresh, stem-like, early memory CD19 CAR T-cell therapy manufactured using a rapid decentralized platform, showed robust in vivo expansion and durable persistence. Treatment with GLPG5101 led to promising efficacy and safety across indications in heavily pretreated pts with R/R NHL.
- |||| GLPG5101 / Galapagos
New P1/2 trial: Atalanta-1: A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma (clinicaltrials.gov) - Aug 19, 2024
P1/2, N=195, Recruiting, Sponsor: Galapagos NV
- GLPG5101 / Galapagos
SEVEN-DAY VEIN-TO-VEIN POINT-OF-CARE (Hall 2) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2534;
The safety profile of GLPG5101 is comparable to that of other CD19-targeted CAR-T therapies. CRRs were high in Ph1 and Ph2 in a heavily pretreated patient population.
- GLPG5101 / Galapagos
Seven-Day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5101) in Relapsed/Refractory NHL: Results from the Phase 1 Atalanta-1 Trial (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_2548;
With this novel PoC manufacturing model, an early phenotype of less differentiated CAR T cells is preserved, demonstrating rapid GLPG5101 in vivo expansion and durable persistence post-infusion . The trial is ongoing, and updated data will be presented.
- GLPG5101 / Galapagos
Initial Clinical Results of Point-of-Care Manufactured GLPG5101 in RR NHL (Poster Area) - Jan 24, 2023 - Abstract #EHAEBMTCART2023EHA_EBMT_CART_70;
P1/2
GLPG5101 manufactured at the point-of-care, administered as a fresh product with a vein-to-vein time of 7 days, is a new CAR-T therapeutic option with limited toxicity and promising efficacy. Safety and efficacy results of this ongoing Phase I/II study, including CAR T-cell expansion and persistence data will be updated at the time of this meeting.
- GLPG5101 / Galapagos
Initial Clinical Results of Atalanta-1, a Phase I/II Trial of Point-of-Care Manufactured GLPG5101 (19CP02) in RR NHL (Hall D (Ernest N. Morial Convention Center)) - Nov 4, 2022 - Abstract #ASH2022ASH_6467;
P1/2
Safety and efficacy results of this ongoing phase 1 trial, including CAR T-cell expansion and persistence data will be updated at the time of this meeting. The Atalanta-1/CP0201-NHL study is sponsored by CellPoint BV, a Galapagos company, with EU registration number 2021-003272-13.